Familial hypercholesterolemia, commonly abbreviated FH, is an inherited disorder characterized by exposure to low-density lipoproteins above normal levels from the earliest stages of life. In classical monogenic forms, the defect affects LDL clearance through the LDL receptor pathway, increasing LDL cholesterol and accelerating atherosclerosis. Its defining feature is not only how high LDL is at diagnosis, but how long the arteries have already been exposed to that concentration.
The heterozygous form affects approximately one person in 300, with variation between populations and diagnostic criteria. The homozygous form, clinically understood as a spectrum of severe biallelic disease, is much rarer, on the order of one person in 300,000. Founder effects and consanguinity modify these frequencies. The disease remains underdiagnosed: it may first be recognized after a coronary event, whereas identification in childhood could limit many years of avoidable exposure.
FH is not synonymous with every instance of hypercholesterolemia occurring in a family. Several relatives may have elevated LDL because of polygenic predisposition or shared factors without an identifiable monogenic variant. The distinction is useful for counseling and screening but must not lead to underestimation of a severe phenotype when molecular testing is negative. Management begins with actual risk and exposure, while genetic testing clarifies the mechanism when possible.
The most frequently involved gene is LDLR, which encodes the LDL receptor. Pathogenic variants may impair receptor synthesis, transport to the membrane, particle binding, internalization, or recycling. Functional classification distinguishes abnormalities with residual activity from nearly null defects: this difference contributes to disease severity and response to therapies that increase receptor availability. The gene name alone therefore does not describe the full biological severity.
APOB variants may impair LDL recognition by the receptor, whereas gain-of-function PCSK9 variants promote receptor degradation. The common result is less efficient clearance, but phenotypes may differ. Biallelic LDLRAP1 abnormalities cause a recessive form by impairing the adaptor protein required for internalization. Other disorders of sterol metabolism produce similar presentations and must be distinguished from classical FH.
For autosomal dominant forms, a heterozygous parent has a 50% chance of transmitting the variant to each child, irrespective of sex or the outcomes of previous pregnancies. When both parents carry causal variants, a child may inherit two affected alleles. Combinations include homozygosity for the same variant, compound heterozygosity for different variants in the same gene, and digenic forms. Molecular descriptions should specify these distinctions without assuming that all combinations have identical prognoses.
The phenotype also depends on genetic modifiers, Lp(a) levels, diet, age, and associated conditions. A variant classified as pathogenic must be consistent with the mechanism and clinical presentation; a variant of uncertain significance is insufficient to label an entire family as affected. Even within one family, age at diagnosis, smoking, and treatment can produce major differences in cardiovascular history.
Reduced LDL clearance increases the opportunities for apoB-containing particles to cross the endothelium and become retained in the intima. Cumulative exposure promotes plaque formation and progression, with especially marked consequences in coronary arteries. High cholesterol from childhood does not mean that the child already has critical stenosis: it means that the process can begin long before symptoms, and that time is a modifiable component of prevention.
In severe biallelic disease, inadequate clearance may cause extreme concentrations and early involvement of the aortic root, coronary ostia, and valvular or supravalvular structures. Anatomical damage may progress even when late treatment improves laboratory values. This explains the need to combine lipid control with cardiac surveillance, without treating LDL-C as the only measure of established disease.
Tendon deposits result from accumulation of lipids and foam cells in tissues and indicate substantial exposure. They do not directly measure the extent of coronary stenosis and are not present in every patient, particularly when diagnosis is early. Their absence must not become an exclusion criterion, just as their presence requires differential diagnosis when the rest of the presentation is inconsistent.
Heterozygous FH may remain asymptomatic for many years. Suspicion arises from persistently high LDL, an affected relative, or premature coronary disease. Regular exercise and normal weight do not exclude the diagnosis. In children, waiting for symptoms forfeits the main preventive opportunity because clinical manifestations are not the criteria for deciding whether to investigate an at-risk family.
The history should establish untreated values, age at first detection, and previous treatments, together with events in first- and second-degree relatives. Family history requires diagnoses and ages, not merely a nonspecific report of heart disease. Myocardial infarctions, revascularizations, sudden deaths, xanthomas, and available genetic results should be recorded. An apparently healthy parent may be affected but still young, effectively treated, or never tested.
Tendon xanthomas typically involve the Achilles tendons and the extensors of the hands; they may be nodular or cause diffuse thickening. Corneal arcus at a young age strengthens suspicion but loses specificity with advancing age. Xanthelasmas can accompany the disease but are not diagnostic alone. In homozygous forms, cutaneous or tuberous xanthomas may appear during the first years of life, including at pressure sites.
Cardiovascular examination looks for aortic murmurs, signs of heart failure, and abnormal pulses. Angina, exertional syncope, or dyspnea in severe forms requires prompt assessment for coronary and aortic disease. Ostial lesions and possible outflow tract obstruction may complicate the presentation. A child with suspected homozygous FH should be referred promptly to an experienced center, even if the initial physical examination is unremarkable.
Examination also considers aggravating causes and conditions mimicking FH: signs of hypothyroidism, edema and proteinuria, cholestasis, hepatomegaly, or atypical neurological manifestations. A history of gastrointestinal disorders, cytopenias, or unusual deposits may suggest different sterol metabolism defects. A familial diagnosis must not become a label that prevents identification of a correctable acquired component.
Initial assessment requires a reliable lipid profile and, where circumstances allow, confirmation that the abnormality persists. In adults, untreated LDL-C of at least 190 mg/dL warrants consideration of FH, but sensitivity and specificity depend on age and context. A lower concentration may still be compatible with FH in someone already treated or carrying a variant with a milder phenotype. Increased triglycerides do not exclude concomitant FH but broaden the differential diagnosis and may reduce the accuracy of calculated LDL-C.
The Dutch Lipid Clinic Network combines family history, personal vascular history, physical signs, untreated LDL-C, and genetic findings. For LDL-C it assigns 1 point at 155–190 mg/dL, 3 points at 191–250, 5 at 251–325, and 8 above 325 mg/dL; tendon xanthomas score 6 points, corneal arcus before age 45 scores 4, and an identified causal variant scores 8. Total scores indicate possible FH at 3–5, probable FH at 6–8, and definite FH above 8. Historical categories must be applied using the system's definitions, without arbitrarily adding alternative findings within the same category.
Within family history, 1 point is assigned for a first-degree relative with premature coronary or vascular disease or LDL-C above the 95th percentile; 2 points are assigned for tendon xanthomas or corneal arcus in a first-degree relative, or for LDL-C above the 95th percentile in a child younger than 18. In personal history, premature coronary artery disease scores 2 points, and premature cerebrovascular or peripheral vascular disease scores 1. For each group, the finding with the highest score is used. A total below 3 makes FH unlikely under this tool but does not exclude every genetic cause of hypercholesterolemia or remove a treatment indication based on LDL levels.
Under the Dutch criteria, premature events are generally defined as occurring before age 55 in men and 60 in women. Other systems, such as Simon Broome, use different thresholds and combinations: a hybrid criterion created by selecting the conditions most favorable to diagnosis from each system would be inappropriate. Adult scores should not be transferred unmodified to children, in whom vascular history and tendon signs inevitably have limited sensitivity.
In children, interpretation combines concentration, an affected parent, and the presence of a familial variant. The 2026 EAS consensus proposes LDL-C above 175 mg/dL for clinical FH; the threshold is lowered to above 135 mg/dL with a family history of premature atherosclerotic disease or elevated baseline cholesterol in a parent, and to above 115 mg/dL when a parent has a genetic diagnosis. The new thresholds improve sensitivity compared with previous criteria and require exclusion of secondary causes and specialist assessment. Demonstration of a causal variant in a child defines genetically confirmed FH.
When the familial variant is known, targeted testing avoids waiting until LDL becomes extremely elevated. Discordance between a pathogenic variant and unusually low LDL may require investigation of modifiers or conditions masking the phenotype. Subsequent treatment decisions take account of age, concentration, and severity. Confirming inheritance does not mean prescribing identical treatment to an infant, a heterozygous child, and an adolescent with biallelic disease.
Homozygous FH should be suspected in the presence of a severe phenotype, particularly with untreated LDL-C above approximately 400 mg/dL, early xanthomas, or both parents having hypercholesterolemia. This approximate threshold from the 2023 consensus is not absolute: variants with residual activity, ongoing treatments, and genetic combinations may produce lower values. The former expectation of levels above 500 mg/dL risks delaying some diagnoses. Treatment must not be withdrawn to obtain an “untreated” value if doing so exposes the patient to risk.
Secondary causes should be ruled out or quantified with TSH, renal assessment and proteinuria, liver tests, and medication history as indicated. Lp(a) testing is useful both to identify its prognostic contribution and because its cholesterol is included in standard LDL-C measurements. A fixed arithmetic correction for Lp(a) does not replace specialist assessment and may misclassify the patient.
Sitosterolemia, due to biallelic ABCG5 or ABCG8 defects, may cause xanthomas and early disease, sometimes with hematological abnormalities; plant sterol measurement is required. Lysosomal acid lipase deficiency may combine dyslipidemia with hepatomegaly and liver disease. Cerebrotendinous xanthomatosis has a different metabolic profile, often with early cataracts and neurological manifestations. These features allow targeted testing rather than indiscriminate rare-disease panels for every patient.
Molecular analysis investigates variants in genes consistent with clinical suspicion, including copy-number changes as well as sequence variants where appropriate. A pathogenic or likely pathogenic result interpreted in context makes family screening more precise. A negative result may reflect polygenic predisposition, unrecognized variants, or technical limitations; it does not invalidate a well-supported clinical diagnosis. Counseling must explain these limitations before and after testing.
Cascade screening begins with the index case and extends to relatives, initially first-degree relatives and then branches in which additional affected people are identified. If the variant is known, targeted testing is easier to interpret than repeated broad panels. Without an informative variant, lipid profiles and clinical criteria remain essential. Diagnosis in minors has immediate medical value because it may alter prevention during childhood; consent, age-appropriate communication, and confidentiality must be protected.
Reverse cascade screening, in which identification of a child leads to diagnosis of parents and other relatives, can identify adults who remain asymptomatic. Universal or selective screening programs depend on healthcare organization, but having an already affected family provides a concrete indication for investigation. One normal result obtained under unrepresentative conditions should not close the assessment when a defined familial variant is present.
Assessment of arterial damage is proportionate to age, severity, symptoms, and history. In selected adults, coronary calcium scoring or plaque imaging may refine risk, but a negative examination does not remove the indication to control inherited exposure. Not every heterozygous child needs coronary CT angiography. In the homozygous form, echocardiographic surveillance of the aortic root and valve, and planned coronary assessment at an expert center, are needed, with modalities and intervals adapted to risk.
Intima-media thickness measurements have been valuable in studies of natural history and early response but do not replace individual clinical assessment and must not become a prerequisite for authorizing therapy. Subsequent investigations distinguish exposure from damage, identify lesions requiring specific intervention, and establish a baseline for follow-up. Assessment also includes Lp(a), blood pressure, smoking, glycemia, and kidney function because risk is not determined by the variant alone.
In surveillance of homozygous FH, echocardiography describes aortic anatomy, gradients, ventricular function, and possible consequences of overload. Preserved systolic function does not exclude significant ostial coronary lesions. Selection of anatomical coronary imaging and possible functional assessment must therefore reflect disease history and the quality of previous investigations, not only reported symptoms. Planning invasive or surgical procedures requires accurate knowledge of aortic and coronary anatomy because calcification and proximal lesions may alter risk and feasibility.
Treatment must begin early enough to reduce the cumulative burden. Appropriate diet, physical activity, and avoidance of smoking are essential but do not correct the receptor defect. In children, diet must preserve growth, energy intake, and essential fatty acids; extreme restriction or blaming family habits is inappropriate. Drug treatment is not a failure of lifestyle measures but a response to the disease mechanism.
In adults with FH but no cardiovascular disease or additional major risk factors, the European reference category is generally high risk, with an LDL-C target below 70 mg/dL and at least a 50% reduction. Atherosclerosis or other major features indicate very high risk, with a target below 55 mg/dL and a similar percentage reduction. Even more intensive targets may be considered with recurrent events. These indications do not justify automatically applying general-population risk scores to a young person with FH.
The foundation is a statin at the highest appropriate tolerated intensity, often combined early with ezetimibe because high starting levels make monotherapy insufficient. Anti-PCSK9 antibodies allow substantial additional lowering in forms retaining receptor activity. Bempedoic acid and inclisiran can be introduced according to need, indications, and tolerability. Choice should consider availability, adherence, and outcome evidence, distinguishing cardiovascular trials from lipid-lowering studies alone.
In heterozygous children, the 2026 EAS consensus proposes starting treatment earlier, ideally from age 6 when needed. It indicates LDL-C targets of no more than 135 mg/dL from age 6 to under 10, and no more than 115 mg/dL from age 10, or from age 6 in the presence of major aggravating factors. Application requires specialist assessment and respect for individual drug approvals: a strategic recommendation does not make every medication interchangeably available at every age.
Pediatric treatment is titrated with monitoring of efficacy, tolerability, growth, and pubertal development. Statins are the reference treatment; ezetimibe and, in appropriate patients, anti-PCSK9 therapies can address insufficient lowering. Twenty-year follow-up of children previously treated with statins showed favorable carotid thickness and event outcomes compared with their affected parents' generation; as a long-term observational comparison, it is not equivalent to randomization maintained for twenty years.
In homozygous FH, treatment is urgent and combined. Statins and ezetimibe may provide benefit, but the response to receptor-dependent therapies varies with residual activity. A very limited response to an anti-PCSK9 treatment must be recognized by measurement rather than continuing an insufficient strategy through inertia. Apheresis and agents with receptor-independent mechanisms may be required as early as childhood, according to severity and local center capabilities.
Distinguishing relative from absolute response is essential in extreme forms. A considerable percentage reduction may still leave a patient far above target if baseline was exceptionally high; conversely, a small additional percentage reduction may remove a substantial amount of cholesterol from everyday exposure. Combinations are therefore assessed according to levels achieved over time and organ damage, without expecting one drug to correct the entire defect. Biallelic severity warrants early, intensive care even when conventional targets remain difficult to achieve.
Lipoprotein apheresis periodically removes atherogenic particles, producing a sharp fall followed by rebound between sessions. The immediately postprocedure concentration does not describe average exposure over the interval. Frequency, vascular access, tolerability, and impact on school or work must be incorporated into planning. Any reduction in session frequency after introducing new medications requires documentation of overall control, not just the lowest measured value.
Evinacumab, an antibody against ANGPTL3, can reduce LDL-C even when LDLR function is severely impaired; ELIPSE HoFH demonstrated substantial lipid reduction when added to existing treatment. Lomitapide inhibits microsomal triglyceride transfer protein and reduces production of apoB-containing lipoproteins. It requires management of gastrointestinal effects, hepatic fat accumulation, and drug interactions, as well as a dedicated nutritional plan. Lipid-lowering efficacy and direct demonstration of benefit for clinical events must not be presented as identical findings.
Therapeutic surveillance includes lipid testing after initiation or changes, assessment for adverse effects, and targeted monitoring of transaminases, CK, and kidney function according to medication and symptoms. Patients receiving lomitapide or apheresis have additional needs. When symptoms are attributed to a statin, a tolerated dose or agent is sought and supplemented with other mechanisms, avoiding prolonged interruption of all treatment. Adherence should be discussed without confusing practical difficulty with unwillingness on the patient's part.
Pregnancy requires planning, medication review, and assessment of maternal risk, particularly in homozygous disease or coronary artery disease. Numerous lipid-lowering treatments are discontinued or avoided in routine practice; any exceptions must be decided by an experienced team according to indications and safety data. Apheresis may retain a role in severe forms. Counseling also covers transmission probabilities, possible partner assessment, and resumption of treatment after pregnancy and breastfeeding.
Bile acid sequestrants, which are not systemically absorbed, may be an option in selected situations, including certain reproductive periods, but their efficacy is limited and they do not replace an adequate strategy in severe disease. Intestinal tolerability, possible interference with absorption of other drugs and vitamins, and triglyceride increases require attention. In children, particularly when dietary restrictions already apply, nutritional monitoring must ensure that pursuing better LDL levels does not compromise growth or adequate intake.
Transition from pediatric to adult services is a critical point for continuity of care. Young people must understand why treatment is required even though it often produces no perceptible symptom improvement, know their phenotype, and receive an agreed monitoring plan. Independence in medication use, reproductive health, physical activity, and addressing concerns deserve attention. Early diagnosis loses part of its advantage if care is interrupted during adolescence.
Prognosis differs greatly between disease recognized early and FH left uncontrolled for decades. Timely prevention can substantially reduce risk but does not guarantee identical outcomes in all genotypes. Age at treatment initiation, average achieved level, Lp(a), smoking, and the presence of established lesions influence the trajectory. Genetic diagnosis informs risk without providing an inevitable individual prediction of age at first myocardial infarction.
Premature coronary artery disease is the most characteristic complication and may manifest as angina, myocardial infarction, need for revascularization, arrhythmias, or sudden death. After an event, secondary prevention demands additional attention to residual exposure and other risk factors. Carotid and peripheral artery disease may coexist, although the relative contribution of FH differs across vascular territories and not all neurological events are atherosclerotic.
In severe forms, aortic disease and coronary ostial involvement may complicate even valve procedures or revascularization. LDL control does not replace correction of a hemodynamically significant obstruction. Painful or bulky xanthomas may have functional consequences, but their regression does not exclude persistent plaques. Management must therefore combine systemic prevention, appropriate anatomical surveillance, and treatment of existing complications.
Family screening ultimately has a collective prognostic value: each new case identified before an event offers an opportunity to interrupt a family history of premature disease. Screening remains useful even when an adult is diagnosed late, because children, siblings, and other relatives may be at a much more favorable stage for prevention.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.